Business
Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company has signed an agreement for CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited ("ASE Group"), to significantly expand its commercial and distribution territory across South Asia to now include Bangladesh, Pakistan, Ne
About this update from Ase Technology Holding Co., Ltd.
[{"type":"text","content":"Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro® and SARAGENE® product line","length":180,"tagName":"p","attribs":{}},{"type":"text","content":"SALT LAKE CITY, March 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company has signed an agreement for CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited ("ASE Group"), to significantly expand its commercial and distribution territory across South Asia to now include Bangladesh, Pakistan, Nepal, and Sri Lanka.","length":606,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Co-Diagnostics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Co-Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":184,"url":"https://media.zenfs.com/en/prnewswire.com/7a89e790bf1cbdd13a473c00e9766ccb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H2z60_r3M0ZmQZYikUZQ5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNA--/https://media.zenfs.com/en/prnewswire.com/7a89e790bf1cbdd13a473c00e9766ccb","width":400,"height":184}},"href":"https://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13.0 billion based on internal analyses and third-party market data. It also supports CoSara's plans to commercialize the CoSara PCR Pro® point-of-care instrument and tests as well as the SARAGENE® product line across the region, subject to applicable regulatory approvals in each jurisdiction. As part of this expansion, CoSara is working to establish distribution channels in these newly added markets, including evaluating regulatory pathways, identifying priority customer segments, and engaging regional distribution partners.","length":681,"tagName":"p"},{"type":"text","content":"Mohal Sarabhai, CEO of CoSara, commented, "South Asia represents a large and ra...